Clinical Oncology Pharmacy (د. نجوي ابراهيم)

18/10/2024

FDA Approves Zolbetuximab in Advanced CLDN18.2+ Gastric/GEJ Adenocarcinoma

Data from the phase 3 SPOTLIGHT trial and the phase 3 GLOW trial supported the approval of zolbetuximab plus chemotherapy in this indication.

23/09/2024

HER3-DXd Significantly Improves PFS Vs Chemo in Advanced EGFR+ NSCLC

HERTHENA-Lung02 investigators will present further data from the trial at a future medical meeting.

04/08/2024

FDA Approves Subcutaneous Daratumumab Regimen in Newly Diagnosed Multiple Myeloma

Data from the PERSEUS trial support the FDA approval of the subcutaneous daratumumab-containing regimen in newly diagnosed multiple myeloma.

04/08/2024

Can Mutations in DNA Damage Repair Genes Predict Cisplatin Response in Muscle-Invasive Urothelial Carcinoma?

https://www.sciencedirect.com/science/article/abs/pii/S0302283824024539

04/08/2024

FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma

On July 30, 2024, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research & Development, LLC) in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in patients with newly diagnosed multiple myeloma who

25/07/2024

https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300267

The 21-gene recurrence score (RS) assay (Oncotype DX) is used to guide adjuvant chemotherapy use for patients with hormone receptor–positive, HER2 (human epidermal growth factor receptor 2)-negativ...

25/07/2024

www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00203-1/abstract

Neoadjuvant camrelizumab plus apatinib show promising antitumour activity in patients with locally advanced mismatch repair-deficient or microsatellite instability-high colorectal cancer. Immune-related adverse events should be monitored with the utmost vigilance. Organ preservation seems promising....

15/07/2024

https://ajp.amjpathol.org/article/S0002-9440(24)00163-9/fulltext

A number of patients with colon cancer with local or local advanced disease suffer from recurrence and there is an urgent need for better prognostic biomarkers in this setting. Here, the transcriptomic landscape of mRNAs, long noncoding RNAs, snRNAs, small nucleolar RNAs (snoRNAs), small Cajal body....

15/07/2024

https://ascopost.com/news/july-2024/predicting-taxane-induced-peripheral-neuropathy-after-breast-cancer-therapy/?utm_source=TAP%2DEN%2D071224%20%2D%20INTL&utm_medium=email&utm_term=2feed76f38d5dcaf2c2ef411f2d190fa

Researchers have developed a novel tool that may help to predict the risk of experiencing peripheral neuropathy following treatment with taxanes in patients with breast cancer.

02/07/2024

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

The long-term follow-up results of CASSIOPEIA show that including daratumumab in both the induction and consolidation phase and the maintenance phase led to superior progression-free survival outcomes. Our results confirm D-VTd induction and consolidation as a standard of care, and support the optio...

02/07/2024

https://ascopubs.org/doi/10.1200/JCO.24.00278

PURPOSE We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA, and dexamethasone for preventing chemotherapy-induced nausea and vomiting in patients receiving carboplatin-containing chemotherapy. PATIEN...